{"id":315,"date":"2013-07-19T16:21:47","date_gmt":"2013-07-19T07:21:47","guid":{"rendered":"http:\/\/120.29.164.89\/?p=315"},"modified":"2023-08-29T10:44:10","modified_gmt":"2023-08-29T01:44:10","slug":"315","status":"publish","type":"post","link":"https:\/\/www.peptide.co.jp\/en\/new-product\/315.html","title":{"rendered":"[Gly14]-Humanin"},"content":{"rendered":"

New Tool for Alzheimer’s Disease Research!<\/b><\/p>\n

Through functional expression screening (termed a death-trap screening), Professor Nishimoto (KEIO University) and his colleagues identified a cDNA, encoding a novel 24-amino acid-residue peptide, designated as “humanin” [Proc. Natl. Acad. Sci. U.S.A.,<\/i> 98<\/b>, 6336-6341 (2001)]. \"HN\" This peptide abolishes death of neuronal cells caused by multiple different types of familial Alzheimer’s disease gene products and A\u03b2 amyloid.<\/p>\n

Transfection of a plasmid encoding humanin cDNA to F11 neuronal cells suppressed toxicity by either V642I-APP, M146L-PS1, or N141I-PS2 cDNA. The cultured medium of F11 cells transfected with plasmid humanin carried protective activity, and contained bands of the humanin immunoreactivity at 3-4 kDa. Humanin was thus transcribed from coding death-trap clones and secreted into the medium.<\/p>\n

Synthetic humanin protected V642I-APP-transfected F11 cells from death in a dose-dependent manner. After structure-activity relationship study, they found potent analog, that is, a Ser to Gly substituted peptide at position 14. This analog is 1000 times more potent than that of the parent peptide humanin. The [Gly14<\/sup>]-humanin(10 nM) blocks V642I-APP, M146L-PS1, and N141I-PS2 cDNA-induced cell-death. When neurons are pretreated with 10 nM of [Gly14<\/sup>]-humanin, A\u03b21-43-induced death as well as dystrophic changes of neurites are suppressed. \"G14-HN\"<\/p>\n

Although further experiments are required, this potent [Gly14<\/sup>]-humanin will contribute to generate the new Alzheimer’s disease therapeutics targeting for neuroprotection.<\/p>\n\n\n\n\n\n
Code<\/td>\nCompound<\/td>\nPackage<\/td>\n<\/tr>\n
4385-v<\/a><\/td>\n[Gly14<\/sup>]-Humanin<\/td>\n0.5 mg vial<\/td>\n<\/tr>\n
4384-v<\/a><\/td>\nHumanin<\/td>\n0.5 mg vial<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Related Products<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Code<\/td>\nCompound<\/td>\nPackage<\/td>\n<\/tr>\n
4379-v<\/a><\/td>\nAmyloid \u03b2- Protein (Human, 1- 40) [HCl Form]<\/td>\n0.5 mg vial<\/td>\n<\/tr>\n
4307-v<\/a><\/td>\nAmyloid \u03b2- Protein (Human, 1- 40)<\/td>\n0.5 mg vial<\/td>\n<\/tr>\n
4349-v<\/a><\/td>\nAmyloid \u03b2- Protein (Human, 1- 42)<\/td>\n0.5 mg vial<\/td>\n<\/tr>\n
4370-v<\/a><\/td>\nAmyloid \u03b2- Protein (Human, 1- 43)<\/td>\n0.5 mg vial<\/td>\n<\/tr>\n
4367-v<\/a><\/td>\n[Pyr3<\/sup>]-Amyloid \u03b2- Protein (Human, 3- 42)<\/td>\n0.5 mg vial<\/td>\n<\/tr>\n
4309-v<\/a><\/td>\nAmyloid \u03b2- Protein (Human, 25-35)<\/td>\n0.5 mg vial<\/td>\n<\/tr>\n
4359-v<\/a><\/td>\nAmyloid \u03b2- Protein (Human, 1- 16)<\/td>\n0.5 mg vial<\/td>\n<\/tr>\n
4358-v<\/a><\/td>\n\u03b2-Sheet Breaker Peptide iA\u03b25<\/td>\n5 mg vial<\/td>\n<\/tr>\n
14307-v<\/a><\/td>\nAmyloid \u03b2- Protein (Human, 1- 40) Antiserum<\/td>\n0.05 ml vial<\/td>\n<\/tr>\n
14356-v<\/a><\/td>\nAmyloid \u03b2- Protein (Human, 34- 40) Antiserum<\/td>\n0.05 ml vial<\/td>\n<\/tr>\n
14357-v<\/a><\/td>\nAmyloid \u03b2- Protein (Human, 37- 42) Antiserum<\/td>\n0.05 ml vial<\/td>\n<\/tr>\n
14359-v<\/a><\/td>\nAmyloid \u03b2- Protein (Human, 1- 16) Antiserum<\/td>\n0.05 ml vial<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

New Tool for Alzheimer’s Research!<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[2],"tags":[],"acf":[],"_links":{"self":[{"href":"https:\/\/www.peptide.co.jp\/en\/wp-json\/wp\/v2\/posts\/315"}],"collection":[{"href":"https:\/\/www.peptide.co.jp\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.peptide.co.jp\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.peptide.co.jp\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.peptide.co.jp\/en\/wp-json\/wp\/v2\/comments?post=315"}],"version-history":[{"count":1,"href":"https:\/\/www.peptide.co.jp\/en\/wp-json\/wp\/v2\/posts\/315\/revisions"}],"predecessor-version":[{"id":4953,"href":"https:\/\/www.peptide.co.jp\/en\/wp-json\/wp\/v2\/posts\/315\/revisions\/4953"}],"wp:attachment":[{"href":"https:\/\/www.peptide.co.jp\/en\/wp-json\/wp\/v2\/media?parent=315"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.peptide.co.jp\/en\/wp-json\/wp\/v2\/categories?post=315"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.peptide.co.jp\/en\/wp-json\/wp\/v2\/tags?post=315"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}